Under the Papervork Reduction Act of 1995, no persons are required to respon	Approved for use through 11/30/2007. OMB 0651-00 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC to a collection of information unless it exerting a valid OMB control number.
Order the Paperviols Neutobiol Act of 1995, no persons are required to respon	a to a conscion of miorination unless it contains a valid Gwib Control numb

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10591213
Filing Date		2006-08-31
First Named Inventor	LEAR	Y, James
Art Unit		1648
Examiner Name PENG		S, Bo
Attorney Docket Number		0021101-00445

					U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date Name of Patentee of Applicant F		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1									
If you wis	h to a	I dd additional U.S. Pate	nt citatio	n inform	ation pl	L ease click the	Add button.	<u> </u>		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citatio	n information p	olease click the Ad	d butto	on.	
				FOREI	GN PAT	ENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ² i		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1									
If you wis	h to a	L dd additional Foreign F	atent Do	cument	citation	information p	lease click the Add	butto	n	_
			NOM	I-PATE	NT LITE	RATURE DO	CUMENTS			
Examiner Initials* No Discount Properties of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T5				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10591213		
Filing Date		2006-08-31		
First Named Inventor	LEAR	Y, James		
Art Unit		1648		
Examiner Name	PENG	Э, Во		
Attanana Dantat Mandan		0004404 00445		

1	BABINCOVA, M. and BABINEC, P. "Aerosolized VEGF in combination with intravenous magnetically targeted delivery of DNA-nanoparticle complex may increase efficiency of cystic fibrosis gene therapy." Medical hypotheses, 2006, Vol. 67, No. 4, p 1002.	
2	BARTLETT, D. and DAVIS, M. "Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles." Bioconjugate Chem, 2007, 18, p 456-468.	
3	BELLOCQ, N., PUN, S., JENSEN, G. and DAVIS, M. "Transferrin-Containing, Cyclodextrin Polymer-Based Particles for Tumor-Targeted Gene Delivery." Bioconjugate Chem, 2003, 14, p 1122-1132.	
4	BERGEN, J., VON RECUM, H., GOODMAN, T., MASSEY, A. and PUN, S. "Gold Nanoparticles as a Versatile Platform for Optimizing Physicochemical Parameters for Targeted Drug Delivery." Macromolecular Bioscience, 2006, 6, p 506-516.	
5	BRANNON-PEPAS, L. and BLANCHETTE, J. "Nanoparticle and targeted systems for cancer therapy." Advanced Drug Delivery Reviews, 2004, 56, p 1649-1659.	
6	DAI, H., JIANG, X., TAN, G., CHEN, Y., TORBENSON, M., LEONG, K. and MAO, H. "Chitosan-DNA nanoparticles delivered by intrabiliary infusion enhance liver-targeted gene delivery." Int J Nanomedicine, 2006, 1(4), p 507-522.	
7	FARJO, R., SKAGGS, J., QUIAMBAO, A., COOPER, M. and NAASH, M. "Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles." PLoS ONE 1(1): e38. 2006, p 1-8.	
8	HATTORI, Y. and MAITANI, Y. "Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase." Cancer Gene Therapy, 2005, Vol. 12, p	
9	HAYES, M., DRUMMOND, D., HONG, K., ZHENG, W., KHOROSHEVA, V., COHEN, J., NOBLE IV, C., PARK, J., MARKS, J., BENZ, C. and KIRPOTIN, D. "Increased Target Specificity of Anti-HER2 Genospheres by Modification of Surface Cherge, and Degree of PEGylation." Molecular Pharmacoulitesis, 2008, Vol. 3, No. 6, p. 728-738.	
10	HONG, S., LEROUEIL, P., MAJOROS, I., ORR, B., BAKER, Jr, J. and BANASZAK HOLL, M. "The Binding Avidity of a Nanoparticle-Based Multivalent Targeted Drug Delivery Platform." Chemistry & Biology, 2007, 14, p 107-115.	
11	JIN, S. and YE, K. "Nanoparticle-Mediated Drug Delivery and Gene Therapy." Biotechnology Progress, 2007, 23, p 32-41.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10591213		
Filing Date		2006-08-31		
First Named Inventor	LEAR	Y, James		
Art Unit		1648		
Examiner Name PENG		B, Bo		
Attornous Dooleat Number		0021101 00445		

12	KAUL, G. and AMIJI M. "Tumor-Targeted Gene Delivery Using Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles: In Vitro and in Vivo Studies." Pharmaceutical Research, 2005, Vol. 22, No. 6, p 951-961.	
13	KICKHOEFER, V., GARCIA, Y., MIKYAS, Y., JOHANSSON, E., ZHOU, J., RAVAL-FERNANDES, S., MINOOFAR, P., ZINK, J., DUNN, B., STEWART, P. and ROME, L. "Engineering of vault nanocapsules with enzymatic and fluorescent properties." PNA, 2005, Vol. 102, No. 12, p 4348-4352.	
14	MONDALEK, F., ZHANG, Y., KROPP, B., KOPKE, R., GE, X., JACKSON, R. and DORMER, K. "The permeability of SPION over an artificial three-layer membrane is enhanced by external magnetic field." Journal of Nanobiotechnology, 2006, Vol. 4, No. 4.	
15	MYC, A., MAJOROS, I., THOMAS, T. and BAKER, Jr., J. "Dendrimer-Based Targeted Delivery of an Apoptotic Sensor in Cancer Cells." Biomacromolecules, 2007, 8, p 13-18.	
16	PEDERESEN, N., HANSEN, S., HEYDENREICH, A., KRISTENSEN, H. and POULSEN, H. "Solid lipid nanoparticles can effectively bind DNA, streptavidin and biotinylated ligands." European Journal of Pharmaceutics and Biopharmaceutics, 2006, p 165-162.	
17	PENG, W., ANDERSON, D., BAO, Y., PADERA Jr., R., LANGER, R. and SAWICKI, J. "Nanoparticulate Delivery of Suicide DNA to Murine Prostate and Prostate Tumors." The Prostate, 2007, Vol. 67, Issue 8, p 855-862.	
18	RATY, J., LIIMATAINEN, T., WIRTH, T., AIRENNE, K., IHALAINEN, T., HUHTALA, T., HAMERLYNCK, E., VIHINEN-RANTA, M., NARVANEN, A., YLA-HERTTUALA, S. and HAKUMAKI, J. "Magnetic resonance imaging of viral particle biodistribution in vivo." Gene Therapy, 2006, Vol. 13, p 1440-1446.	
19	SCHIFFELERS, R., ANSARI, A., XU, J., ZHOU, Q., TANG, Q., STORM, G., MOLEMA, G., LU, P., SCARIA, P. and WOODLE, M. "Cancer siRNA therapy by lumor selective delivery with ligand-targeted sterically stabilized nanoparticle."	
20	SHI, X., WANG, S., MESHINCHI, S., VAN ANTWERP, M., BI, X., LEE, I. and BAKER Jr., J. "Dendrimer-Entrapped Gold Nanoparticles as a Platform for Cancer-Cell Targeting and Imaging." Small, 2007, Vol. 3, No. 7, p 1245-1252.	
21	SHUKLA, R., THOMAS, T., PETERS, J., DESAI, A., KUKOWSKA-LATALLO, J., PATRI A., KOTLYAR A. and BAKER Jr., J. "HER2 Specific Tumor Targeting with Dendrimer Conjugated Anti-HER2 mAb." Bioconjugate Chemistry, 2006, Vol. 17, No. 5, p 1109-1115.	
22	TAN, K., CHEANG, P., HO, L, LAM, P. and HUI, K. "Nanosized bioceramic particles could function as efficient gene delivery vehicles with target specificity for the spleen." Gene Therapy, 2007, Vol. 14, p 828-835.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

English language translation is attached.

(Not for submission under 37 CFR 1.99)

Application Number		10591213		
Filing Date		2006-08-31		
First Named Inventor	LEAR	Y, James		
Art Unit		1648		
Examiner Name	PENG	G, Bo		
Attorney Docket Number		0021101-00445		

	23		I, W., JIANG, S. and ZHANG, Y. "Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via \(\) \(\) interference." Biomaterials, 2007, 28, p 1565-1571.					
	24		S, Y., WANG, Y., POWELL, R. and CHAN, P. "Polymeric Core-Shell Nanoparticles for Therapeutics." Clinical and crimental Pharmacology and Physiology, 2006, Vol. 33, p 557-562.					
If you wis	h to a	dd add	litional non-patent literature document citation information p	lease click the Add I	outton			
			EXAMINER SIGNATURE					
Examiner Signature		ture		Date Considered				
*EXAMIN	ER: In	itial if	reference considered, whether or not citation is in conforma	ance with MPEP 609	Draw line through a			

Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if

citation if not In conformance and not considered. Include copy of this form with next communication to applicant.